Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment

Gynecologic Oncology

Volumn 143, Issue 1, 2016, Pages 46-53

  Talhouk, Aline ^a   Hoang, Lien N ^a,b   McConechy, Melissa K ^a,c   Nakonechny, Quentin ^a   Leo, Joyce ^a   Cheng, Angela ^d   Leung, Samuel ^d   Yang, Winnie ^a   Lum, Amy ^a   Köbel, Martin ^e   Lee, Cheng Han ^f   Soslow, Robert A ^b   Huntsman, David G ^a   Gilks, C Blake ^a   McAlpine, Jessica N ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CALGARY LABORATORY SERVICES   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DIRECTED DNA POLYMERASE EPSILON; EXONUCLEASE; MISMATCH REPAIR PROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; CLASSIFICATION; COHORT ANALYSIS; ENDOMETRIAL NEOPLASMS; GENETICS; MORTALITY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; PROGNOSIS;

EID: 84979590908     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.07.090     Document Type: Article

References (40)

1. [1] Arnold, M., Pandeya, N., Byrnes, G., Renehan, A.G., Stevens, G.A., Ezzati, M., et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 16 (2015), 36–46.
2. [2] Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–E386.
3. [3] Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M., Matrisian, L.M., Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74 (2014), 2913–2921.
4. [4] Jung, K.W., Won, Y.J., Kong, H.J., Oh, C.M., Lee, D.H., Lee, J.S., Prediction of cancer incidence and mortality in Korea, 2014. Cancer Res. Treat. 46 (2014), 124–130.
5. [5] Hoang, L.N., McConechy, M.K., Kobel, M., Han, G., Rouzbahman, M., Davidson, B., et al. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am. J. Surg. Pathol. 37 (2013), 1421–1432.
6. [6] Gilks, C.B., Oliva, E., Soslow, R.A., Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am. J. Surg. Pathol. 37 (2013), 874–881.
7. [7] Han, G., Sidhu, D., Duggan, M.A., Arseneau, J., Cesari, M., Clement, P.B., et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod. Pathol. 26 (2013), 1594–1604.
8. [8] Guan, H., Semaan, A., Bandyopadhyay, S., Arabi, H., Feng, J., Fathallah, L., et al. Prognosis and reproducibility of new and existing binary grading systems for endometrial carcinoma compared to FIGO grading in hysterectomy specimens. Int. J. Gynecol. Cancer 21 (2011), 654–660.
9. [9] British Columbia Cancer Registry CSaO, Population Oncology. Endometrial Cancer Rates ≤ 50 yo in British Columbia. 2013–2014.
10. [10] Cancer Genome Atlas Research N, Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., et al. Integrated genomic characterization of endometrial carcinoma. Nature 497 (2013), 67–73.
11. [11] Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br. J. Cancer 2015;113:299–310.
12. [12] Stelloo, E., Bosse, T., Nout, R.A., MacKay, H.J., Church, D.N., Nijman, H.W., et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod. Pathol., 2015.
13. [13] Karateke, A., Tug, N., Cam, C., Selcuk, S., Asoglu, M.R., Cakir, S., Discrepancy of pre- and postoperative grades of patients with endometrial carcinoma. Eur. J. Gynaecol. Oncol. 32 (2011), 283–285.
14. [14] Sany, O., Singh, K., Jha, S., Correlation between preoperative endometrial sampling and final endometrial cancer histology. Eur. J. Gynaecol. Oncol. 33 (2012), 142–144.
15. [15] Wang, X.Y., Pan, Z.M., Chen, X.D., Lu, W.G., Xie, X., Accuracy of tumor grade by preoperative curettage and associated clinicopathologic factors in clinical stage I endometriod adenocarcinoma. Chin. Med. J. 122 (2009), 1843–1846.
16. [16] Ben-Shachar, I., Pavelka, J., Cohn, D.E., Copeland, L.J., Ramirez, N., Manolitsas, T., et al. Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstet. Gynecol. 105 (2005), 487–493.
17. [17] McConechy, M.K., Talhouk, A., Leung, S., Chiu, D.S., Yang, W., Senz, J., et al. Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Clin. Cancer Res., 2016.
18. [18] McConechy, M.K., Talhouk, A., Li-Chang, H.H., Leung, S., Huntsman, D.G., Gilks, C.B., et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol. Oncol. 137 (2015), 306–310.
19. [19] Landis, J.R., Koch, G.G., The measurement of observer agreement for categorical data. Biometrics 33 (1977), 159–174.
20. [20] Batista, T.P., Cavalcanti, C.L., Tejo, A.A., Bezerra, A.L., Accuracy of preoperative endometrial sampling diagnosis for predicting the final pathology grading in uterine endometrioid carcinoma. Eur. J. Surg. Oncol., 2016.
21. [21] Mitchard, J., Hirschowitz, L., Concordance of FIGO grade of endometrial adenocarcinomas in biopsy and hysterectomy specimens. Histopathology 42 (2003), 372–378.
22. [22] Helpman, L., Kupets, R., Covens, A., Saad, R.S., Khalifa, M.A., Ismiil, N., et al. Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer. Br. J. Cancer 110 (2014), 609–615.
23. [23] Murali, R., Soslow, R.A., Weigelt, B., Classification of endometrial carcinoma: more than two types. Lancet Oncol. 15 (2014), e268–e278.
24. [24] Bendifallah, S., Canlorbe, G., Collinet, P., Arsene, E., Huguet, F., Coutant, C., et al. Just how accurate are the major risk stratification systems for early-stage endometrial cancer?. Br. J. Cancer, 2015.
25. [25] Bendifallah, S., Darai, E., Ballester, M., Predictive modeling: a new paradigm for managing endometrial cancer. Ann. Surg. Oncol. 23 (2016), 975–988.
26. [26] Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., Darai, E., Endometrial cancer. Lancet 387 (2016), 1094–1108.
27. [27] Colombo, N., Creutzberg, C., Amant, F., Bosse, T., Gonzalez-Martin, A., Ledermann, J., et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int. J. Gynecol. Cancer 26 (2016), 2–30.
28. [28] Omenn, G.S., On best practices: the Institute of Medicine scheme for developing, validating, and demonstrating clinical utility of omics-based diagnostic and predictive tests. Proteomics Clin. Appl. 7 (2013), 748–755.
29. [29] Stelloo, E., Nout, R.A., Naves, L.C., Ter Haar, N.T., Creutzberg, C.L., Smit, V.T., et al. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Gynecol. Oncol. 133 (2014), 197–204.
30. [30] Parker, W.H., Feskanich, D., Broder, M.S., Chang, E., Shoupe, D., Farquhar, C.M., et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet. Gynecol. 121 (2013), 709–716.
31. [31] Parker, W.H., Broder, M.S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet. Gynecol. 113 (2009), 1027–1037.
32. [32] Rocca, W.A., Grossardt, B.R., Shuster, L.T., Oophorectomy, estrogen, and dementia: a 2014 update. Mol. Cell. Endocrinol. 389 (2014), 7–12.
33. [33] Shuster, L.T., Rhodes, D.J., Gostout, B.S., Grossardt, B.R., Rocca, W.A., Premature menopause or early menopause: long-term health consequences. Maturitas 65 (2010), 161–166.
34. [34] Karnezis, A.N., Hoang, L.N., Coatham, M., Ravn, S., Almadani, N., Tessier-Cloutier, B., et al. Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Mod. Pathol. 29 (2016), 302–314.
35. [35] Hoang, L.N., Lee, Y.S., Karnezis, A.N., Tessier-Cloutier, B., Almandani, N., Coatham, M., et al. Immunophenotypic features of dedifferentiated endometrial carcinoma insights from BRG1/INI1-deficient tumors. Histopathology, 2016.
36. [36] Kobel, M., Meng, B., Hoang, L.N., Almadani, N., Li, X., Soslow, R.A., et al. Molecular analysis of mixed endometrial carcinomas shows clonality in most cases. Am. J. Surg. Pathol. 40 (2016), 166–180.
37. [37] Soslow, R.A., Endometrial carcinomas with ambiguous features. Semin. Diagn. Pathol. 27 (2010), 261–273.
38. [38] Hussein, Y.R., Weigelt, B., Levine, D.A., Schoolmeester, J.K., Dao, L.N., Balzer, B.L., et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod. Pathol. 28 (2015), 505–514.
39. [39] Stelloo, E., Nout, R.A., Osse, E.M., Jurgenliemk-Schulz, I.J., Jobsen, J.J., Lutgens, L.C., et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer - combined analysis of PORTEC cohorts. Clin. Cancer Res., 2016.
40. [40] Talhouk, A., M.K., M., L, S., Y, W., L, A., S, J., et al. A clinically applicable molecular-based classification system for endometrial cancers. J. Clin. Oncol., 2016 (ASCO poster presention: Abstract No: 5518).